4 completed, 1 terminated, 1 withdrawn. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Stage IIIB Skin Melanoma: new trials by email Literature Review of Stage IIIB Skin Melanoma trials Research Report on Stage IIIB Skin Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Imatinib Mesylate, Laboratory Biomarker Analysis, Pembrolizumab - Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma | Phase 1 / Phase 2 | Withdrawn | Joanne Jeter | 2016-11-04 | 2018-04-05 | |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2013-03-26 | 2022-07-22 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2002-10-01 | 2015-01-26 |
Melanoma (6) · Carcinoma, Renal Cell (3) · Astrocytoma (2) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Oligodendroglioma (2) · Ovarian Neoplasms (2) · Urinary Bladder Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Ependymoma (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin Neoplasms (6) · Skin and Connective Tissue Diseases (6) · Adenocarcinoma (3) · Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
pembrolizumab (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Imatinib Mesylate (1) · Nivolumab (1) · Peptides (1) · Protein Subunit Vaccines (1) · Sirolimus (1) · cediranib (1)
National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · Joanne Jeter (1) · Rutgers, The State University of New Jersey (1)
United States (4) · Canada (1)
Biren Saraiya (1) · Joanne Jeter, MD (1) · John Kane (1) · Kunle Odunsi (1) · Sebastien Hotte (1) · Walter Urba (1)
PMID 35780243, PMID 39462179, PMID 40132910
P30CA016056 (1), P30CA016058 (1), P30CA072720 (1), R01CA158318 (1), R21CA099265 (1), U01CA132123 (1)